Dapagliflozin-Metformin in Obese T2D After GLP-RA: Assessing Newer Possibilities- Dr Bharat Saboo Dr Bharat Saboo26 May 2026 10:37 AM ISTGlobally and in India, T2DM prevalence continues to rise, with obesity as one of its most important clinical drivers, reported in nearly 60-90% of...
Delhi HC Upholds Ban on Unapproved FDC Drugs, Backs DCGI Action Susmita Roy2 May 2026 7:30 PM ISTNew Delhi: The Delhi High Court has cleared the path for cancelling licences related to the manufacture, sale, marketing, and distribution of...
Dapagliflozin and Sitagliptin FDC in Indian T2D: 5 Points Clinicians May Like to Know - Dr K Baraneedharan Dr. K. Baraneedharan9 April 2026 12:00 PM ISTThe burden of T2DM is increasing worldwide, with enormous implications for morbidity and mortality. Early and effective intervention is essential to...
Integrating Dapagliflozin and Sitagliptin FDC for Optimizing Outcomes in Type-2 Diabetes with Cardiometabolic-Based Chronic Disease (CMBCD) patients - Dr Kaushik Biswas Dr. Kaushik Biswas28 March 2026 10:27 AM ISTIntroduction India's T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a...
SC Seeks Centre, DCGI Response on Micro Labs' Plea Against Anti-Diabetic FDC Ban Susmita Roy26 Feb 2026 10:26 PM ISTNew Delhi: The Supreme Court sought responses from the Union government and the Drug Controller General of India regarding an appeal filed by Micro...
Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026 Dr. Bhumika Maikhuri23 Feb 2026 10:30 AM ISTIn this episode of Diabetes Wellness Forum, titled, "Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026", Dr Nandita Mohan from...
DTAB Sub-Panel to Reassess 29 'Irrational' FDCs Flagged by Kokate Committee: Report Susmita Roy17 Feb 2026 11:00 PM ISTNew Delhi: In a major move to strengthen drug safety and rational prescribing practices, regulators have initiated a renewed examination of 29...
Efficacy and Safety of Dapagliflozin-Vildagliptin in Indian T2DM Patients with CV Risk Factors Dr. Bhumika Maikhuri30 Jan 2026 12:58 PM ISTThe Fixed-Dose Combination (FDC) of Dapagliflozin 5 mg + Vildagliptin 50 mg demonstrated significant improvements in Glycemic Control, Metabolic...
Venus Remedies Secures Marketing Authorisation For Ceftazidime, Avibactam FDC In Indonesia sheeba farhat15 Jan 2026 2:20 PM ISTThis approval represents Venus Remedies' first marketing authorization in the anti-infective segment in Indonesia and also enables the first generic...
Unique Pharma Asked To Revise BE Study Protocol for Cilnidipine-Metoprolol FDC Parthika Patel22 Oct 2025 8:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has directed Unique Pharmaceutical...
Exemed Pharma's Empagliflozin-Vildagliptin Combo Rejected by CDSCO Panel Over Questionable Clinical Use Susmita Roy8 Oct 2025 8:04 PM ISTNew Delhi: In a setback to Exemed Pharmaceuticals, the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO)...
Vildagliptin-Dapagliflozin FDC Effective in High CV Risk Indian T2DM Patients: Findings from Latest DAa-ViNCI Study Dr. Bhumika Maikhuri6 Oct 2025 12:22 PM ISTIn a new study, fixed-dose combination (FDC) of vildagliptin and dapagliflozin demonstrated substantial efficacy and good tolerability in managing...
